Transforming Women's Cancer Care: Innovations in Ovarian and Cervical Cancer Research

By City of Hope

Ovarian and cervical cancer(s) continue to pose significant threats to women’s health, with late detection and limited treatment options contributing to high mortality rates. Ovarian cancer affects nearly 20,000 women annually in the U.S., with a survival rate below 50%. Cervical cancer, despite the availability of the HPV vaccine, is increasing in prevalence. City of Hope is responding with a bold, research-driven approach that is reshaping the future of women’s cancer care. 

Innovative Therapies on the Horizon 

One of the most promising developments is a novel CAR T cell therapy for metastatic ovarian cancer. Led by Lorna Rodriguez-Rodriguez, M.D., Ph.D., this therapy targets TAG72, a protein found only on ovarian cancer cells. By training the immune system to attack these cells, the therapy offers a highly precise and potentially transformative treatment. Early results have been so encouraging that Dr. Rodriguez-Rodriguez and her team are seeking FDA approval for expanded trials.  

Another groundbreaking approach involves an engineered oncolytic virus developed by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D. This “friendly” virus selectively destroys cancer cells while sparing healthy tissue. Originally successful in treating prostate cancer, it is now being adapted for ovarian cancer, with clinical trials planned to evaluate its effectiveness in metastatic cases. 

Revolutionizing Early Detection 

Early detection is critical in improving survival rates, and City of Hope is pioneering noninvasive screening methods. In a clinical trial led by Mihae Song, M.D., and Patrick Pirrotte, Ph.D., researchers have successfully identified ovarian cancer biomarkers in samples collected via routine pap tests. This breakthrough could pave the way for accessible, widespread screening using simple blood and urine tests. 

Preventing Relapse Through Micro-Metastasis Research 

A major challenge in ovarian cancer treatment is the sudden relapse experienced by some patients after achieving remission. Until recently, the cause of these relapses was unknown. Dr. Rodriguez and Hua Yu, Ph.D., have discovered previously undetectable micro-metastases that evade treatment and trigger fatal recurrences. Their research aims to develop therapies that target these hidden threats, potentially preventing relapse and saving women’s lives. 

Leadership Driving Change 

City of Hope’s Women’s Cancers Program is now led by Hope S. Rugo, M.D., a distinguished physician-scientist with over 500 peer-reviewed publications. Dr. Rugo has been instrumental in advancing clinical trials and establishing new standards of care. Her work includes the development of scalp-cooling caps to prevent chemotherapy-induced hair loss and a steroid mouthwash to reduce side effects from targeted therapies. As the Editor in Chief of the ASCO educational book and a recipient of multiple prestigious awards, Dr. Rugo brings unmatched expertise and vision to the program. 

About City of Hope

City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the United States, and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. Established independently, National Cancer Institute-designated comprehensive cancer center that is ranked among the nation’s top cancer centers by U.S. News & World Report. At its core, City of Hope’s uniquely integrated model spans cancer care, advanced research, academics and training, and a broad philanthropy program that powers its work.